NKGN (NKGen Biotech) Issuance of Debt : $12.57 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Issuance of Debt?

NKGen Biotech's Issuance of Debt for the three months ended in Sep. 2024 was $2.74 Mil.

NKGen Biotech's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was $12.57 Mil.

NKGen Biotech Issuance of Debt Historical Data

The historical data trend for NKGen Biotech's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Issuance of Debt Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

Issuance of Debt

20.90

23.00

26.51

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Issuance of Debt	Get a 7-Day Free Trial					12.79	0.06	1.47	8.29	2.74

NKGen Biotech Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.57 Mil.

NKGen Biotech Issuance of Debt Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.